You are viewing: Canada Genotyping Assay Market analysis
Part of: Genotyping Assay Market (Global)

The Canada Genotyping Assay Market was valued at $807 Million in 2024 and projected to reach to $1436.7 Million by 2029, representing a compound annual growth rate of 12.2%. Canada's genotyping assay market is positioned for sustained growth through 2029, driven by increasing adoption of precision medicine across healthcare systems and growing patient demand for personalized treatment options.

Canada Genotyping Assay Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada Genotyping Assay Market Trends and Insights

  • This expansion in Canada reflects increasing adoption of precision medicine, rising demand for personalized healthcare solutions, and growing investment in genomic research infrastructure across Canadian healthcare institutions and diagnostic laboratories.
  • Canada's strong regulatory framework and emphasis on advanced healthcare technologies are positioning the country as a key market for genotyping assay innovations. The Canadian market benefits from a well-established healthcare system, significant government funding for genomic research, and increasing collaboration between academic institutions and private sector players.
  • Canada's commitment to precision medicine initiatives and the integration of genotyping assays into clinical practice are driving market penetration across oncology, pharmacogenomics, and infectious disease diagnostics.
  • Between 2024 and 2029, Canada is expected to see accelerated adoption of next-generation sequencing and targeted genotyping platforms, supported by growing awareness among healthcare providers and patients regarding the benefits of genetic testing..

Key Market Statistics

  • CAGR (2024-2029) 12.2% CAGR
  • Market Size, 2024 ~USD 807 Million
  • Forecast, 2029 ~USD 1436.7 Million
  • Country Canada

Canada Genotyping Assay Market Overview

Market Valuation Growth :

Canada's genotyping assay market reached $807.0 million in 2024 and is projected to grow to $1,436.7 million by 2029, demonstrating strong market expansion driven by healthcare modernization and genomic adoption.

Precision Medicine Adoption :

Canadian healthcare institutions are increasingly integrating genotyping assays into clinical practice, supported by government funding for genomic research and personalized medicine initiatives across provinces.

Genomic Research Infrastructure :

Investment in Canadian genomic research centers and biotech hubs is accelerating, with major institutions leveraging genotyping assays for disease prevention, drug development, and population health studies.

Regulatory Support & Funding :

Canadian regulatory bodies and provincial health systems are actively supporting genomic testing adoption, with increased funding for precision healthcare programs and integration into standard clinical protocols.

Canada Genotyping Assay Market Dynamics

  • Provincial health authorities are investing in genomic infrastructure, while Canadian biotech companies are expanding their genotyping capabilities to meet domestic and international demand. The 12.2% CAGR reflects strong momentum in clinical diagnostics, pharmacogenomics, and research applications.
  • Key growth drivers include aging population demographics, rising prevalence of genetic disorders, and government initiatives supporting genomic medicine integration.
  • Canadian healthcare providers are increasingly recognizing the clinical and economic value of genotyping assays in improving patient outcomes and reducing healthcare costs..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Danaher Corporation

    Key Takeaways

    • Canada's genotyping assay market is valued at $807.0 million in 2024 and is forecast to reach $1,436.7 million by 2029, growing at a 12.2% CAGR.
    • Canada's strong healthcare infrastructure and government support for genomic research are key drivers of market expansion.
    • Precision medicine adoption and integration of genotyping assays into clinical workflows are accelerating across Canadian healthcare systems.
    • Canada's market growth is supported by increasing demand for personalized diagnostics in oncology, pharmacogenomics, and infectious disease management.

    Genotyping Assay Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment PHARMACOGENOMICS (Application)
    Forecast Period 2024–2029
    Growth Rate CAGR of 13.8% from 2024 to 2029
    Largest Segment REAGENTS & KITS (Product & Service)
    Market Size Base Year (Billions) ~USD 19.44 (2024)
    Revenue Forecast (Billions) ~USD 37.1 (2029)
    Segments Covered Product & Service, Type, Technology, Application, End User

    Canada Genotyping Assay Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product & Service

    • Bioinformatics
    • Genotyping Services
    • Instruments
    • Reagents & Kits

    By Type

    • Amplified Fragment Length Polymorphism
    • Analyzers
    • Digital Polymerase Chain Reaction
    • Next-Generation Sequencing
    • Pyrosequencing
    • Real-Time Polymerase Chain Reaction
    • Restriction Fragment Length Polymorphism
    • Sanger Sequencing
    • Sequencers & Amplifiers
    • Services
    • Single-Strand Confirmation Polymorphism
    • Software

    By Technology

    • Capillary Electrophoresis
    • Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry
    • Microarrays
    • Other Technologies
    • Polymerase Chain Reaction
    • Sequencing

    By Application

    • Agricultural Biotechnology
    • Animal Genetics
    • Diagnostics & Personalized Medicines
    • Other Applications
    • Pharmacogenomics

    By End User

    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES133183.2200.9221.5245.7274.1307.5346.811.5
    DIAGNOSTIC LABORATORIES162.6178.4197.1218.9244.6274.7310.4352.612.3
    OTHER END USERS155.3130.1141.7155.2171189.5211.1236.510.8
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES216.2239.6267.3299.8338.1383.3436.9500.713.4
    TOTAL667731.3807895.5999.41121.61265.91436.712.2

    Target Audience

    • Diagnostic Companies & IVD Manufacturers : Need Canada-specific market data to assess market size, growth potential, and competitive opportunities for genotyping assay product launches and expansion in Canadian healthcare systems.
    • Pharmaceutical & Biotech Firms : Require insights into Canadian pharmacogenomics adoption and precision medicine trends to support drug development strategies and personalized medicine initiatives in the Canadian market.
    • Healthcare Providers & Hospital Networks : Seek market intelligence on genotyping assay adoption trends, clinical applications, and ROI data to inform procurement decisions and integration of genomic testing into Canadian clinical workflows.
    • Investment & Private Equity Firms : Need comprehensive Canada market analysis, growth forecasts, and competitive landscape data to evaluate investment opportunities in Canadian genomics and precision medicine companies.
    • Government & Healthcare Policy Makers : Require market data and trend analysis to inform genomic medicine policy development, healthcare funding allocation, and strategic planning for precision medicine integration across Canadian provinces.

    Key Companies in the Canada Genotyping Assay Market

    CompanyHQOwnershipStrongest segments
    SEQUENOM,INC.United StatesPrivate CompanyMaterniT21 PLUS and VisibiliT NIPT,MaterniT21 GENOME and microarray (NextView),HerediT carrier screening (CF, Ashkenazi, SMA, fragile X),
    DECODE GENETICSIcelandPrivate CompanyTarget discovery and validation for Amgen pipeline,Large-scale genome sequencing and analytics services,Data access, licensing, and collaborative research programs,
    TRANSGENOMIC, INC.United StatesPublic CompanyOncology and pharmacogenomics clinical trial services,Clinical oncology testing services (patient diagnostics and monitoring),Multiplexed ICE COLD-PCR reagents and technology licensing,
    IMMUCOR, INC.United StatesPrivate CompanyTransfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS),
    GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines OE,Commercial Engines Services & MRO,Defense & Propulsion Technologies – Engines,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    ILLUMINA, INC.United StatesPublic CompanySequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Array-based instruments and consumables,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology,Life Sciences,Diagnostics,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health),PCR and enzymes (qPCR, dPCR, research PCR kits),
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Tools,Other / Services and Software,
    MERCK KGAAGermanyPublic CompanyLife Science (lab reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, immunology, fertility, rare diseases),Electronics (semiconductor materials, specialty gases, display and OLED materials),
    STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics and qPCR systems (Biomark X9 and related assays),Services, software, and other consumables,
    REVVITYUnited StatesPublic CompanyDiagnostics instruments and automation (AutoDELFIA, GSP, EUROIMMUN, IDS-iSYS, EUROLabWorkstation),Diagnostics reagents, assays, and kits (prenatal, newborn, autoimmune, infectious disease, T-SPOT),Life science reagents and consumables (BioLegend, Dharmacon, NEXTFLEX, AlphaLISA portfolio),
    PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read instruments and consumables (Onso platform),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION platforms and consumables,MinION and portable platforms,GridION and mid-throughput systems,

    SEQUENOM,INC.

    Sequenom, Inc. is a private molecular diagnostics company founded in 1994 in the United States with 434 employees. The company specializes in genetic testing and analysis.

    DECODE GENETICS

    Decode Genetics is a private genomics and biotechnology company founded in 1996 in Iceland with 331 employees. The company conducts genetic research and develops diagnostics based on genomic data.

    TRANSGENOMIC, INC.

    Transgenomic, Inc. is a public molecular diagnostics company founded in 1997 in the United States with 19 employees. The company develops genetic testing and analysis technologies.

    IMMUCOR, INC.

    Immucor, Inc. is a private blood bank and transfusion diagnostics company founded in 1982 in the United States with 1,125 employees. The company provides immunohematology and transfusion medicine solutions.

    GENERAL ELECTRIC

    General Electric is a public multinational conglomerate founded in 1892 in the United States with 57,000 employees. The company operates across diverse industries including healthcare, energy, and industrial sectors.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public life sciences and diagnostics company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.

    ILLUMINA, INC.

    Illumina, Inc. is a public genomics and sequencing company founded in 1998 in the United States with 8,625 employees. The company develops DNA sequencing and genetic analysis technologies.

    DANAHER CORPORATION

    Danaher Corporation is a public diversified conglomerate founded in 1969 in the United States with 59,000 employees. The company operates across life sciences, diagnostics, and environmental solutions.

    QIAGEN

    Qiagen is a public molecular diagnostics and life sciences company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample preparation, assay, and sequencing technologies.

    EUROFINS SCIENTIFIC

    Eurofins Scientific is a public laboratory services and diagnostics company founded in 1987 in Luxembourg with 65,694 employees. The company operates a global network of laboratories providing testing and analysis services.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a public life sciences and diagnostics company founded in 1999 in the United States with 18,000 employees. The company manufactures analytical instruments and laboratory equipment.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public life sciences and diagnostics company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures clinical diagnostics and life science research products.

    MERCK KGAA

    Merck KGaA is a public pharmaceutical and life sciences company founded in 1668 in Germany with 59,077 employees. The company provides pharmaceuticals, chemicals, and laboratory solutions globally.

    STANDARD BIOTOOLS

    Standard Biotools is a public life sciences instrumentation company founded in 1999 in the United States with 387 employees. The company develops microfluidics and single-cell analysis technologies.

    REVVITY

    Revvity is a public life sciences and diagnostics company founded in 1937 in the United States with 11,000 employees. The company provides analytical instruments, reagents, and software solutions.

    PACBIO

    PacBio is a public genomics sequencing company founded in 2000 in the United States with 485 employees. The company develops long-read DNA sequencing technologies.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a public genomics sequencing company founded in 2005 in the United Kingdom with 1,316 employees. The company develops portable DNA and RNA sequencing technologies.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for Canada ($807M in 2024) with 5-year forecasts to validate investment decisions and competitive positioning in the Canadian genotyping assay sector.
    • Regional Growth Drivers Analysis : Understand Canada-specific factors driving 12.2% CAGR, including precision medicine adoption, provincial healthcare policies, and genomic research funding to identify market opportunities.
    • Competitive Landscape Intelligence : Benchmark against Canadian market dynamics and identify key players, market gaps, and expansion opportunities specific to Canada's healthcare and biotech ecosystem.
    • Strategic Market Entry Planning : Develop informed go-to-market strategies for Canada with localized insights on regulatory requirements, healthcare system integration, and customer adoption patterns in the genotyping assay space.
    • Investment & Partnership Decisions : Make data-driven decisions on Canadian market investments, partnerships, and acquisitions with comprehensive market forecasts and growth trajectory analysis through 2029.

    Frequently asked questions

    What is the current size of Canada's genotyping assay market?

    Canada's genotyping assay market was valued at $807.0 million in 2024 and is expected to grow to $1,436.7 million by 2029.

    What is the projected growth rate for Canada's genotyping assay market?

    Canada's genotyping assay market is projected to grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2029.

    What factors are driving growth in Canada's genotyping assay market?

    Key drivers include increasing adoption of precision medicine, government funding for genomic research, growing demand for personalized healthcare, and integration of genotyping assays into clinical practice across Canadian healthcare institutions.

    Which applications are leading Canada's genotyping assay market growth?

    Oncology, pharmacogenomics, and infectious disease diagnostics are among the leading applications driving genotyping assay adoption in Canada.

    How does Canada's market compare to global genotyping assay market trends?

    Canada's 12.2% CAGR is slightly below the global average of 13.8%, reflecting Canada's mature healthcare system and steady, sustainable market expansion driven by precision medicine initiatives.

    RESEARCH METHODOLOGY

    The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the genotyping assay market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Breakdown Of Primary Participants:

    Genotyping  Assay Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME

    DESIGNATION

    F. Hoffmann-La Roche Ltd. (Switzerland)

    Marketing Manager

    Thermo Fisher Scientific, Inc. (US)

    Senior Product Manager

    QIAGEN N.V. (Netherlands)

    Marketing Manager

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the home healthcare market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the genotyping assay market have been determined through primary and secondary research
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Global genotyping assay Market Size: Bottom-Up Approach

    Genotyping  Assay Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Global genotyping assay Market Size: Top-Down Approach

    Genotyping  Assay Market Size, and Share

    Data Triangulation

    After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Genotyping is used to study the differences in the genetic makeup (specific genome variants) of cells, microorganisms, plants, animals, and individuals. These differences in genotypes are determined by studying individual DNA sequences using biological assays and comparing them with other reference sequences. This process has wide applications in the field of life sciences, including animal genetics, diagnostic research, & pharmacogenomics, agricultural biotechnology, and personalized medicine.

    Key Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global genotyping assay market by product and services, technology, application, enduser, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall genotyping assay market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries.
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report

    Country Information

    • Additional country-level analysis of the genotyping assay market

    Company profiles

    • Additional five company profiles of players operating in the genotyping assay market.

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the genotyping assay market

    Get the Full Genotyping Assay Market Report

    Full forecast, segment splits, and company analysis for all Genotyping Assay Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status